



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12P 21/02, C07K 1/00		A1	(11) International Publication Number: WO 90/01555 (43) International Publication Date: 22 February 1990 (22.02.90)
(21) International Application Number: PCT/DK89/00193 (22) International Filing Date: 14 August 1989 (14.08.89) (30) Priority data: 4521/88 12 August 1988 (12.08.88) DK (71) Applicant (for all designated States except US): CARLSBERG BIOTECHNOLOGY LTD. A/S [DK/DK]; Tagensvej 16, DK-2200 Copenhagen N (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): AASMUL-OLSEN, Stig [DK/DK]; Skodsborgvej 410, st.tv., DK-2942 Skodsborg (DK). THORBEC, Pia [DK/DK]; Sdr. Jagtvej 39, DK-2970 Hørsholm (DK). WIDMER, Fred [CH/DK]; Carlsberg Biotechnology Ltd. A/S, Tagensvej 16, DK-2200 Copenhagen N (DK). HANSEN, Søren [DK/DK]; Tomsgaardsvej 102, DK-2400 Copenhagen NV (DK).			(74) Agent: HOFMAN-BANG & BOUTARD A/S; Adelgade 15, DK-1304 Copenhagen K (DK). (81) Designated States: AU, DK, FI, HU, JP, US. Published With international search report.
(54) Title: A PROCESS FOR ENZYMATIC PRODUCTION OF DIPEPTIDES OR STRUCTURALLY RELATED COMPOUNDS			
(57) Abstract Dipeptides H-A-B-Y, wherein A is an α - or ω -amino acid residue, B is an α -aminocarboxylic, aminophosphonic acid or aminosulfonic acid residue, and Y is OH, H or a C-terminal protective group, are produced by reacting a substrate component: H-A-OR ¹ or H-A-NR ² R ³ , wherein R ¹ , R ² , R ³ are alkyl, aryl or aralkyl or R ² and R ³ are H, with a nucleophile component selected from aminocarboxylic acids or their amides, esters, aldehydes or ketones: H-B-NR ² R ³ , H-B-OR ⁴ or H-B-R ⁸ , wherein B, R ² and R ³ are as defined above, R ⁴ and R ⁸ are alkyl, aryl or aralkyl or R ⁸ is H, or aminophosphonic or aminosulfonic acids, in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases, preferably a serine or thiolendoprotease, lipase, esterase or glycosidase in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y. The process allows for production of LL-, LD-, DL- and DD-dipeptides without risk of racemization in a simple and economic manner.			


FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

A process for enzymatic production of dipeptides or structurally related compounds

The present invention concerns a process for enzymatic
5 production of dipeptides and derivatives of dipeptides and having the general formula



10 wherein A represents an optionally side-chain protected L- or D- α -amino acid residue or ω -amino acid residue and B represents an optionally side-chain protected L- or D- α -aminocarboxylic acid residue which may be the same as or different from A, and L- or D-aminophosphonic acid residue
15 or L- or D-aminosulfonic acid residue or the corresponding ω -amino acids or salts and hydrates thereof, and Y is OH, H, alkyl, aryl, aralkyl or a C-terminal blocking group, or BY represents an amino alcohol residue



wherein B^1 is a decarboxy derivative of the aminocarboxylic acids as defined with relation to B, and Y^1 is H, alkyl, aryl or aralkyl.

25 In recent years there has been an increasing interest in dipeptides and dipeptide derivatives optionally containing an amino acid residue of D-configuration, with a view to their potential pharmacological effects, such as e.g.
30 antibiotics. Likewise, there has been a great interest in dipeptides within fields such as artificial nutrition - human as well as veterinary -sweeteners and within agrochemistry, such as e.g. herbicides.

35 Such dipeptides H-A-B-Y can be produced by means of known chemical coupling reactions, but all these methods share

the feature that, generally, it is necessary to protect the amino acids involved - A and B - on the amino group and the carboxylic acid group, respectively, and frequently also on the side chains if these carry functional groups. Further, there is an inherent risk of side reactions during the chemical coupling step because of the reagents and conditions employed, a major side reaction being racemization, particularly of the A-component. By replacing the chemical coupling step with an enzymatic coupling step proceeding under mild conditions, such side reactions and racemization can be avoided, yielding a stereochemically pure product.

The presence of amino- and carboxyl protective groups is mandatory in chemical coupling and has generally been regarded as mandatory also in prior art enzymatic coupling using endoproteases.

This adds several undesired features to these processes seriously afflicting their process economy on an industrial scale, particularly apparent in dipeptide synthesis.

The disadvantages are concerned with the introduction of these groups, as well as their removal and presence during process operation, increasing overall process cost and time and affecting overall yield.

Typical examples of amino protective groups commonly used are those of the carbobenzoxy (Z-) and tert-butoxycarbonyl (Boc-) type, which are of a molecular weight comparable to those of the amino acid residues. Firstly, the protective groups will have to be introduced in the starting materials by means of appropriate costly agents in a separate reaction step followed by an isolation step. While present, these hydrophobic groups often have a

drastical effect upon the solubility of the intermediates and reaction products, and may afflict both the nature and the amount of solvents required in their processing as well as ease of purification and of deprotection. The
5 deprotection will also take place in a separate step with a following purification step.

For this purpose a series of reactions are available, but with the exception of catalytical hydrogenation, posing
10 industrial problems of its own, these methods are occurring under violent, often strongly acidic or basic conditions, frequently giving rise to a series of side reactions, resulting in an impure product or demanding laborious purification.

15 The last steps in this relatively long series of synthesis steps may thus be a rather comprehensive deprotection to obtain the desired peptides, and, owing to the almost inevitable secondary reactions, rather laborious
20 purification procedures are frequently required to provide a product with the desired high purity.

A dipeptide which has attracted great attention in recent years is L-Asp-L-Phe-methylester, also known as aspartame,
25 and derivatives thereof which has found extended use as sweeteners. The chemical synthesis of aspartame is entailed with the above-mentioned drawbacks.

Attempts to avoid amino terminal protection in the
30 production of aspartame and its derivatives have led to microbial fermentation approaches, like the fermentation processes described in EP-A1-074095, EP-A2-102529 and EP-A2-154472. This technique is fundamentally different from synthetic approaches and relies on specific organisms for
35 aspartame, and is thus not generally applicable in connection with other dipeptides. In addition, the yields

are low and recovery from the fermentation broth laborious.

The above-mentioned shortcomings in the known processes for the production of aspartame are confirmed in EP-A2-269390. In this application a method for producing L-Asp-L-Phe-alkylesters is claimed which comprises reacting in a solvent medium L-aspartic acid alpha ester or L-aspartic acid alpha amide with L-phenylalanine alkyl ester in the presence of an enzyme, microorganism containing the enzyme, enzyme containing fraction of a microorganism, or enzyme immobilized on solid support, said enzyme being capable of forming L-aspartyl-L-phenylalanine alkyl ester by condensation of the L-aspartic acid alpha ester or L-aspartic acid alpha amides and L-phenylalanine alkyl ester.

It is seen that an enzyme must be used which has specific esterase or amidase activity against Asp, but not against Phe. The only enzyme mentioned is the extracellular protease with esterolytic activity of *Staphylococcus aureus* V8.

While therefore the applicability of N- α -unprotected Asp-esters or amides is suggested - along with N-protected or β -esters or amides - the disclosure of one specific enzyme for the use in the production of a specific peptide supported only by one example where rather peculiar reaction conditions are used, viz. 5 times excess of substrate components, this reference does not by far provide a general teaching of the applicability of N-unprotected substrate components in dipeptide synthesis catalyzed by amidase or esterase enzymes.

Thus, it is an obvious advantage in terms of overall process economy to be able to avoid protective groups,

also on the amino and carboxy terminus. In some cases, it may be of interest to be able to produce a dipeptide having side-chain protection, but no terminal protection, and it will be shown that it is possible in the process according to this invention, starting from side-chain protected, but amino unprotected starting materials. In this case, the same advantages of mild reaction conditions and overall process economy may be obtained. If desired, the side-chain protective group may be removed by chemical or enzymatic means, generally under milder conditions than amino protective groups.

The enzyme catalyzed coupling reactions enabling the use of optionally side-chain unprotected amino acid derivatives and an optionally C-terminal unprotected B-component (nucleophile) are known. See e.g. the DK Patent Specification No. 155613 as well as the corresponding EP Patent Specification No. 17 485 (EP-B1-17485), incorporated herein by reference.

Briefly, EP-B1-17485 describes a process for producing peptides by reacting a substrate component selected from i.a. amino acid esters and amino acid amides with an amine component (nucleophile) selected from i.a. L-amino acid amides, L-amino acids or L-amino acid esters in the presence of an L-specific serine or thiol carboxypeptidase enzyme.

If a dipeptide is to be produced by the process of EP-B1-17485, the substrate component is obligatory an N-terminal protected amino acid derivative, and the constituent amino acid is obligatory an L-amino acid.

As described in EP-A1-278787, (incorporated by reference) and other applications claiming priority from DK appln. 725/87 filed on February 13, 1987 it was surprisingly

found that the serine and thiol carboxypeptidases used in EP-B1-17485 are capable of utilizing N-unprotected amino acid esters or amides as a substrate component in controlled reactions for synthesis of dipeptides and
5 dipeptide derivatives, and that it was possible to suppress a possible oligomerization of the substrate.

Admittedly, it has long been known that some endoproteases can catalyze oligomerization of certain N-unprotected
10 amino acid esters with L-configuration, (Fruton, J.S. Advances in Enzymology, 53: 239-306, 1982) but it has never been attempted to use this for production of dipeptides which are not simple dimers. Generally, the results of such oligomerizations have been a mixture of a
15 series of oligomers, sometimes long. The degree of oligomerisation and complexity of the mixture depend on the solubility of the products formed. Also it should be mentioned that the mere fact that a given enzyme can hydrolyze a particular N- α unprotected amino acid
20 derivative does not automatically lead to a similar ability to catalyze coupling reactions involving the same derivative. See the references cited by Andersen, A.J. in "Peptides, Structure and Function". Proc. of the Ninth ann. peptide symposium, Eds. Deber, C.M. et al., Pierce
25 (1985), p. 355.

For this reason the use of serine and thiol endoproteases for peptide synthesis has been limited to the use of amino and carboxy terminal protected starting materials, as
30 exemplified by US-A-4.086.136, where e.g. papain, stembromelein, ficin, chymopapain and chymotrypsin are mentioned.

Furthermore, for these enzymes free amino acids have so far generally been regarded as unsuitable as amino
35 components as noted by Y.W. Mitin et al., Int. J. Peptide

Protein Res., Vol. 23 (1984), p. 528-534.

The above-mentioned amino and carboxy terminal protected starting materials are also mandatory if aspartate
5 endoproteases e.g. pepsin are used as exemplified by US-A-3.972.773, and if metallo endoproteases are used, as exemplified by the synthesis of Z-AspPheOMe.PheOMe-salt in EP-A1-009585. In these condensation type reactions it is
10 further mandatory that the substrate component is on the free α -carboxylic acid form, as exemplified in EP-A2-220923.

The use of amino and carboxy terminal protected starting materials has also been considered mandatory for
15 nonproteases, e.g. esterases with amidase activity, Blair West et al., Tetrahedron letters, Vol. 28. No. 15, p. 1629-32, (1987), who used porcine pancreatic lipase, Candida cylindracea lipase and pig liver esterase in organic media, optionally containing an aqueous buffer.

20 Cellulases in turn, have so far only been used synthetically for polymerisation condensation type reactions of completely free β -amino acids as described by Kitazume, T. et al., J. Fluorine Chem. 36 (1987), p. 225-
25 236.

The synthesis of the diastereomeric dipeptides of DL, LD and DD-configuration as well as peptides containing β -amino acid residues from amino-unprotected substrate
30 components has so far not been possible with carboxypeptidases except as described with relation to EP-A1-278787 nor in general with any proteolytical enzymes (Class EC 3.4). Some efforts have been made with a different class of enzymes, aminoacyl-t-RNA-synthetase
35 (Class EC 6.1) as exemplified by EP-A1-086053. In this case a specific enzyme must be used for each type of amino

acid residue, and furthermore, expensive Co-factors like ATP are required. At the same time, yields are very poor, so even though some product was isolated and identified, typically a ten fold excess of Co-factor and a hundred
5 fold excess of nucleophile and up to a thousand fold excess of enzyme by weight was required.

A recent study by Gaertner et al., Proteins: Structure, Function and Genetics 3: 130-137 (1988) indirectly
10 confirms the prejudice against using N- α -unprotected amino acids as substrate components in enzymatic peptide synthesis. Since a major problem earlier encountered is secondary hydrolysis of the newly synthesized product, an attempt was made to decrease water activity in the
15 reaction medium by using organic solvents. Gaertner et al. reports dipeptide synthesis using chymotrypsin which had been chemically modified to enhance its solubility in organic media. Using a number of N- α -protected amino acid esters as substrates and amino acid amides as nucleophiles
20 N- α -protected dipeptide amides were obtained in good yields in a benzene medium. Thus, α -Bz-Lys-Phe-NH₂ was obtained in a yield of more than 98% by reacting α -Bz-Lys-OMe with Phe-NH₂. However, when using ϵ -Z-LysOEt, i.e. a side-chain protected but N- α -unprotected lysine ester, no
25 ϵ -Z-Lys-Phe-NH₂ was formed. Gaertner et al do not comment on this result, but it indicates that they apparently believed that amino group protection of the substrate component was compulsory.

30 The present invention which represents a further development of the invention according to EP-A1-278787 resides on the surprising finding that the capability of utilizing N- α -unprotected amino acid esters and amides of the substrate component in controlled reactions for
35 synthesis of dipeptides and dipeptide derivatives is not limited to serine or thiol carboxypeptidases, but also


possible with amidase or esterase enzymes generally, in particular serine endoproteases, thiol endoproteases, lipases and esterases.

5 Again, it was surprisingly found that also N- α -unprotected amino acid derivatives of D-configuration can be used as substrates in these reactions, so that, in addition to LL-dipeptides, it is also possible to synthesize DL-dipeptides. The reaction rate for D-substrates, however,
10 is generally somewhat lower than for L-substrates under uniform conditions, but the difference in rate is much smaller than for the corresponding N-protected amino acid esters, the D-substrate being reacted at a rate which is much smaller than the rate for the L-substrate; Purdie et
15 al., Biochem. Biophys. Acta, 268 (1972), 523. There are, however great individual differences between the enzymes in this respect. Synthesis yields are often just as high with the unprotected D-substrates in relation to the unprotected L-substrates.

20

It is known that certain endoproteases are capable of utilizing a nucleophile component having D-configuration in reactions with N-protected substrate components. Thus, depending on the actual sequence it is possible to
25 synthesize dipeptides having LL-, DL-, LD- or DD-configuration by the process according to the invention.

The process of the invention is thus characterized by reacting a substrate component, which is an amino acid
30 derivative having the formula



35 wherein A is as defined above, R¹ represents alkyl, aryl or aralkyl optionally substituted with inert substituents

10


or an α -des-amino fragment of an amino acid, and R^2 and R^3 are the same or different and each represents hydrogen, alkyl, aryl or aralkyl optionally substituted with inert substituents,

5

with a nucleophile component selected from


(a) amino acids having the formula

10



wherein B is an aminocarboxylic acid residue as defined above,

15 (b) amino acid amides having the formula




20

wherein B is an aminocarboxylic acid residue as defined above, and R^2 and R^3 have the above meaning, except that when R^2 represents hydrogen, R^3 may also represent hydroxy or amino,

25


(c) amino acid esters having the formula



30 wherein B is an aminocarboxylic acid residue as defined above, and R^4 represents alkyl, aryl or aralkyl,

(d) optionally acid group protected straight chain or branched aminophosphonic acids or aminosulfonic acids


35 having the formula



wherein R^5 , R^6 and R^7 independently represent hydrogen, alkyl, aryl or aralkyl, x is 1-6 and z is 2-12,

5

(e) amino acid aldehydes or ketones or derivatives thereof having the formula



10

wherein B^1 is as defined above, Y^2 is O or a functional derivative thereof, preferably a ketal, and R^8 is H, alkyl, aryl or aralkyl, and

15 (f) amino alcohols having the formula



wherein B^1 and Y^1 have the above meaning

20

in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y and/or, if
25 desired, converting the resulting dipeptide derivative to a salt or hydrate.

Examples of useful amino acids include aliphatic amino acids, such as monoaminomonocarboxylic acids, e.g. glycine
30 (Gly), alanine (Ala), valine (Val), norvaline (Nval), leucine (leu), isoleucine (iso-Leu) and norleucine (Nleu), hydroxy amino acids, such as serine (Ser), threonine (Thr) and homoserine (homo-Ser), sulfur-containing amino acids, such as methionine (Met) or cystine (CysS) and cysteine
35 (CysH), monoaminodicarboxylic acids, such as aspartic acid (Asp), glutamic acid (Glu) and amides thereof, such as


asparagine (Asn) and glutamine (Gln), diaminomono-carboxylic acids, such as ornithine (Orn) and lysine (Lys), arginine (Arg), aromatic amino acids, such as phenylalanine (Phe) and tyrosine (Tyr), as well as
5 heterocyclic amino acids, such as histidine (His), proline (Pro) and tryptophan (Trp). As examples of useful amino compounds of a more unusual structure may be mentioned penicillamine (Pen), aminophosphonic acids, such as
10 alanine-phosphonic acid (AlaP), aminosulfonic acids, such as taurine (Tau), ω -amino acids, such as β -alanine (BAla), iso amino acids, such as α -methylalanin (Aib), amino acids substituted with inert substituents, e.g. halogen or
nitro, or the aldehyde, ketones, ketals or alcohols derived from e.g. alanine. As mentioned, they may be
15 included in D-form in the substrate component and they may also be present in D-form in the nucleophile component.

It will be understood that the definitions given for the group Y in the peptide derivative of the formula H-A-B-Y
20 are reflected in the various nucleophile components, stated in claim 1. Thus, (b) and (c) both contain C-terminal blocking groups, while Y = H corresponds to an amino acid aldehyde and Y = alkyl, aryl or aralkyl corresponds to an amino ketone. If desired a functional
25 derivative of an amino ketone may be used as nucleophile, e.g. a ketal, oxime or sulfite.

As in the process according to EP-A1-278787, the advantages of the process of the present invention over
30 the mentioned known methods are minimum or no side chain protection, no N-protection of the substrate component which may have both D- and L-configuration, no risk of racemization, few synthesis steps and an expected relatively pure end product, which in combination provides
35 an extremely simple and economic method of production.

Preferred substrate components are esters in which R^1 is a straight or branched alkyl having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, amyl, hexyl, heptyl and octyl, or the aralkyl group benzyl. Particularly expedient nucleophile components are amino acid amides, in which R^2 is H, and R^3 is H or C_1 - C_6 alkyl, or amino acid esters in which R^4 is a straight or branched alkyl having 1 to 6 carbon atoms such as the above-mentioned ones. As mentioned, R^1 may be alkyl, aryl or aralkyl optionally substituted with inert substituents, e.g. hydroxy or nitro.

The invention also comprises the processes involving intermediate formation of a peptide containing the group



following which this group may be cleaved to form a carboxylic acid group. This cleavage may be catalyzed by another enzyme or the same enzyme as was used to form the peptide, albeit under different reaction conditions. Also C-terminal modifications of the group Y may be made.

Enzymes may also be used to cleave side-chain protective groups, applicable enzymes being proteolytic enzymes, lipases and esterases, according to the nature of the protective group, see "The peptides, Analysis, Synthesis, Biology" Vol 9, Special Methods in peptide Synthesis Part C. J.A. Glass, Enzymatic manipulation of Protecting Groups in Peptide Synthesis, Academic Press 1987.

As examples of enzymes possessing esterase and/or amidase activity, and therefore expected to be active as catalysts in the process according to this invention may be

mentioned those listed in the table below.

For a closer description of these enzymes, reference is made to i.a. Perlmann, G. E. et al., in Colowick, S. P. & Kaplan, N. O. (eds.) *Methods of Enzym.* 8 (1966) 19 (1970), 28 (1972), 35 (1975) and 45 (1976), Fruton, S., *Adv. Enzymol.* 53, p. 239, Wiley (1982), Abassi, A. et al. *Biol. Chem. Hoppe-Seyler*, 367, p. 441-45 (1986), Dixon, M. and Webb E. C. "Enzymes", 3rd ed. Longman Group (1979),
10 Torrey, S. (ed.) in "Enzyme Technology, Recent Advances", *Biotech. Rev.* 2, Noyes Data Corporation (1983), and finally Laane, C., Tramper, S., Lilly, M. D. (eds.) "Biocatalysis in Organic Media", Elsevier (1987), Asano, Y. et al., *Angew. Chem.* 101, (1989), p. 511-512, Kitazume, T. et al., *J. Fluorine Chem.* 36 (1987), p. 225-236. all
15 being incorporated by reference.

20

25

30

35

TABEL II. Proteases different from carboxypeptidases:

5		Enzyme	(Abb)	Normal Source
	A) <u>Thiolendo-</u> <u>proteases:</u>	Papain	(P)	Papaya
10		Chymopapain	(CP)	Papaya
		Bromelain	(B)	Pineapple
		Ficin	(F)	Fig (Ficus)
		Clostripain	(CL)	Clostridium histolyticum
15	B) <u>Serineendo-</u> <u>proteases:</u>	Trypsin	(T)	Pancreas
		Chymotrypsin	(CT)	Pancreas
		Elastase	(E)	Pancreas
20		Subtilisin	(S)	Bacillus licheniformis or subtilis
		Thermitase	(TV)	Thermoactino- myces vulgaris
25		Proteinase K	(K)	Tritirachium album
		Valyl-proteinase	(VP)	Candida tropicalis
30		Post Prolin Specific Endopeptidase	(PPSE)	Flavo- bacterium meningo- septicum
35				

	Achromobacter lyti-	
	cus Protease I (AL-I)	Achromobacter
		lyticus
5	Endoproteinase ArgC (AC)	Submaxil-
		laris glands
	Endoproteinase LysC (LC)	Lysobacter
		enzymogenes
	Thrombin (TB)	Blood plasma
10	C) <u>Exopeptidases:</u>	
	Aminopeptidase (EC3.4.11)	Animal,
	particularly from	vegetable,
	Achromobacter sp.	or microbial
15		
	<u>II. Other hydrolases acting on ester bonds</u>	
	Carboxylesterase (EC.3.1.1.1)	Liver
	Arylhydrolase (EC.3.1.1.2)	Plasma
20	Triacylglycerollipase (EC.3.1.1.3)	Animal,
	particularly from	vegetable,
	Porcine Pancreas or	or micro-
	Candida cylindracea or	bial
	Lipolase® (NOVO); (Aspergillus sp.)	
25		
	Acetic ester	
	acetylerase (EC.3.1.1.6)	Animal
		tissue
	Arylglycerol lipase (EC.3.1.1.23)	Animal or
30		vegetable
	<u>III Glycosidases</u>	
	Cellulase (EC.3.2.1.4)	Animal,
	particularly from	vegetable,
35	Trichoderma viride or	or micro-
	Aspergillus niger	bial

The presently preferred enzymes are trypsin, chymotrypsin, subtilisin, elastase, papain, chymopapain, clostripain, porcine pancreatic lipase and *Candida cylindracea* lipase.

- 5 The enzyme used may also be chemically modified or be a biosynthetic mutant of a natural form.

As illustrated more fully below, the process of the invention is rather simple.

10

- The reaction may be performed in an aqueous reaction medium, if desired containing up to 90%, preferably up to 60% of a polar organic solvent which is miscible with water, and compatible with the enzyme under the conditions specified. Preferred solvents are lower alcohols, dimethyl formamide, dimethyl sulfoxide, dimethoxy ethane and ethylene glycol.

- 20 It is important to maintain a rather constant pH value in the reaction mixture. This pH value is between 3 and 11, preferably between 5 and 10.5, more preferably between 6 and 10 and most preferably between 7 and 9.5 and also depends upon the concrete starting materials, the peptide formed and the enzyme.

25

- The reaction may alternatively be performed in a nonaqueous, nonpolar medium being composed of water immiscible organic solvents e.g. benzene, toluene, hexanes, heptanes, octanes, dialkyl ethers, ethyl acetate, ethyl propionate and methylene chloride, etc. which are compatible with enzymes having esterase and/or amidase activity, in particular lipases.

- 30 These essentially apolar reaction media may contain up to 10% water in dissolved form in order to facilitate optimal enzyme performance or reaction stability.

The reaction temperature is preferably room temperature and above, 20 to 50°C, but temperatures in the range 0 to 80°C may be used, if advantageous under the conditions otherwise given. At high solvent conditions subzero or temperatures higher than 80°C may be used.

The concentration of the two reaction components may vary within wide limits, but the nucleophile component is frequently in excess, and to avoid oligomerization of the substrate component, said component is often added in minor portions at intervals during the entire reaction sequence. If a good nucleophile for the enzyme is used in high excess, surprisingly no oligomerization is observed, and high substrate concentrations may be used without side reactions. In case a homo-dipeptide in which A = B is wanted, oligomerization from a single nucleophile can be avoided by using different carboxy protective groups on the substrate and nucleophile component.

Thus, the starting concentration of the substrate component may typically be 0.005 to 2 molar and for the nucleophile component in cases, - where it is added separately, 0.005 to 3 molar. In most situations it is possible to recover excess of the nucleophile component and the hydrolysis product from the substrate component for optional reesterification and reuse. Recycling of the components is particularly easy because of their simple structure and the absence of side reactions and deprotective losses.

The enzyme concentration may likewise vary, but is frequently somewhat higher (5-50 μM) (or even higher, up to \sim 500 μM) than the concentrations appropriate in the use of N-protected amino acid ester substrates, but the amount required for synthetic purposes may be reduced more

than tenfold by using a stable immobilized enzyme preparation, thereby enabling the enzyme to be used in a continuous process.

- 5 The reaction medium may also contain salts, such as NaCl and CaCl_2 , which influences the binding of the enzyme to the substrate and may stabilize the enzyme, as well as a complex binding agent for present metal ions, such as EDTA, and mercaptostabilizing agents such as DTT, BME or
10 Cysteine may used with for instance thiolendoproteases.

This surprising hydrolysis sequence is reflected in the following examples, which illustrate the production of various dipeptides in the process of the invention using
15 various enzymes.

General method for examples 1-13 and 20 et seq.

- The reactions, performed on an analytical scale with a
20 reaction volume of 1 ml, were carried out in a pH-stat, and the selected pH value was kept constant by automatic addition of 1 N NaOH except for the examples with high content of organic solvents or immobilized enzymes, where the conditions are indicated in the individual examples.
25 Reaction temperature was room temperature, unless otherwise stated. The table also includes reaction concentrations, content of organic solvent, product and yield. Reaction times are typically between 0.5 and 5 hours and the enzyme concentrations are typically 5-20 μM .
30 unless otherwise stated.

Product identification and determination of product yield were performed by means of reverse phase HPLC (Waters 6000 A pumps, 660 gradient blender, UK 6 injector) on a C_{18} NOVA
35 PAK column (Waters, RCM) using suitable gradients of elution systems containing 50 mM triethylammonium

than tenfold by using a stable immobilized enzyme preparation, thereby enabling the enzyme to be used in a continuous process.

5 The reaction medium may also contain salts, such as NaCl and CaCl_2 , which influences the binding of the enzyme to the substrate and may stabilize the enzyme, as well as a complex binding agent for present metal ions, such as EDTA, and mercaptostabilizing agents such as DTT, BME or
10 Cysteine may used with for instance thiolendoproteases.

This surprising hydrolysis sequence is reflected in the following examples, which illustrate the production of various dipeptides in the process of the invention using
15 various enzymes.

General method for examples 1-13 and 20 et seq.

The reactions, performed on an analytical scale with a
20 reaction volume of 1 ml, were carried out in a pH-stat, and the selected pH value was kept constant by automatic addition of 1 N NaOH except for the examples with high content of organic solvents or immobilized enzymes, where the conditions are indicated in the individual examples.
25 Reaction temperature was room temperature, unless otherwise stated. The table also includes reaction concentrations, content of organic solvent, product and yield. Reaction times are typically between 0.5 and 5 hours and the enzyme concentrations are typically 5-20 μM .
30 unless otherwise stated.

Product identification and determination of product yield were performed by means of reverse phase HPLC (Waters 6000 A pumps, 660 gradient blender, UK 6 injector) on a C_{18} NOVA
35 PAK column (Waters, RCM) using suitable gradients of elution systems containing 50 mM triethylammonium

phosphate, pH 3.0 from 0% to 80% acetonitrile with a flow of 2 ml/min. Elution was monitored by means of a UV detector (Waters 480) at 230 nm, 254 nm, 278 nm or 290 nm.

- 5 The products were identified by amino acid analysis of fractions from the HPLC analysis, which corresponded to the assumed product peak and/or by HPLC comparison with a chemically synthesized reference product. These were produced according to known principles, usually via
10 reaction between BOC-A-OSu - the tertiary butyloxy carbonyl - succinic imide ester derivative of the substrate amino acid - and the used nucleophile component followed by deblocking of the N-terminal amino acid residue. In all cases, it was possible to separate LL-and
15 DD-dipeptides from the diastomeric DL-and LD-dipeptide products.

- For the products which can only be detected at 230 nm, the product yields were determined by means of the
20 absorption/concentration curve of the chemically synthesized reference compound. For the other products, the yields were determined on the basis of the ratio between the integrated areas below the peaks in the elution chromatogram, corresponding to the product
25 respectively the reactant which absorbs at the wavelength concerned.

- The reaction conditions in the preparative examples 14-17 are described in the individual examples. The reactions
30 were followed on analytical HPLC as described. The enzyme concentrations are generally lower and the reaction times longer than in the corresponding analytical examples, but no attempt to optimize the reaction conditions has been made.

- 21 -

Example 1

5 Trypsin ^{a)} catalyzed synthesis of L,L-dipeptide amides with
L-Arginine ethyl ester (50 mM) as substrate and L-amino acid
amides as nucleophiles at various concentrations in water at
pH 8.5

10	<u>Nucleophile</u>	<u>(conc.)</u>	<u>Product</u>	<u>Yield</u>
	Leucine amide	(0.2 M)	ArgLeuNH ₂	20%
	Leucine amide	(0.7 M)	ArgLeuNH ₂	32%
	Methionine amide	(0.25 M)	ArgMetNH ₂	31%
15	Methionine amide	(0.5 M)	ArgMetNH ₂	52%
	Methionine amide	(1.0 M)	ArgMetNH ₂	90%
	Serine amide	(0.5 M)	ArgSerNH ₂	45%
	Tyrosine amide	(0.5 M)	ArgTyrNH ₂	46%

20

a) 10 μ M

25

30

35

- 22 -

Example 2

Trypsin ^{a)} catalyzed synthesis of diastereomeric L,D- and
5 D,L-dipeptide amides with L- or D-Arginine ethyl ester (50
mM) as substrate and L- or D-Leucine and Methionine amides
as nucleophiles in water at pH 8.5

10	Substrate	Nucleophile	(conc.)	Product	Yield
	D-argOEt	L-Leucine amide	(0.2 M)	argLeuNH ₂	20%
	D-argOEt	L-Leucine amide	(1.0 M)	argLeuNH ₂	30%
	D-argOEt	L-Methionine amide	(0.5 M)	argMetNH ₂	68%
15	L-ArgOEt	D-methionine amide	(1.0 M)	ArgmetNH ₂	5%

a) 10 μ M

20

25

30

35

- 23 -

Example 3

Trypsin ^{a)} catalyzed synthesis of L,L-dipeptide amides using
5 L-amino acid amides (0.5 M) as nucleophiles and L-Lysine or
Histidine ethyl ester (50 mM) as substrate in water at pH
8.5

10	<u>Substrate</u>	<u>Nucleophile</u>	<u>Product</u>	<u>Yield</u>
	LySOEt	Methionine amide	LysMetNH ₂	81%
	LySOEt	Tryptophane amide	LysTrpNH ₂	32%
	LySOEt	Alanine amide	LysAlaNH ₂	5%
15	HisOEt	Methionine amide	HisMetNH ₂	62%

^{a)} 10 μ M

20

25

30

35

- 24 -

Example 4

Alpha-Chymotrypsin a) catalyzed synthesis of L,L-dipeptide
amides using L-Tyrosine ethyl ester (50 mM) as substrate and
5 L-amino acid amides as nucleophiles in water

	Nucleophile	(conc.)	pH	Product	Yield
10	Leucine amide	(0.2 M)	9.0	TyrLeuNH ₂	68%
	Arginine amide	(0.4 M)	8.5	TyrArgNH ₂	90%
	Serine amide	(0.4 M)	8.5	TyrSerNH ₂	75%

15 a) 5 μ M

20

25

30

35

- 25 -

Example 5

Alpha-Chymotrypsin a) catalyzed synthesis of L,D-dipeptide
5 amides using L-Tyrosine ethyl ester (5 or 50 mM) as substrate and D-amino acid amides as nucleophiles in water

	Nucleophile	(conc.)	pH	Product	Yield
10	D-leucine amide	(0.2 M)	9.0	TyrleuNH ₂	17% ^{b)}
	D-isoleucine amide	(0.3 M)	9.0	TyrileNH ₂	23% ^{b)}
	D-serine amide	(0.4 M)	8.5	TyrserNH ₂	35%

15

a) 5 μ M

b) 5 mM substrate

20

25

30

35

- 26 -

Example 6

5 Alpha-Chymotrypsin catalyzed synthesis of D,L-dipeptide amides using D-tyrosine ethyl ester (50 mM) as substrate and L-Leucine amide as nucleophiles in water at pH 9.0

10	Nucleophile	(conc.)	Product	Yield ^{c)}
	L-Leucine amide	(0.2 M)	D,L-tyrLeuNH ₂	40% ^{a)}
	L-Leucine amide	(0.3 M)	D,L-tyrLeuNH ₂	68% ^{b)}

15 a) 50 μ M enzyme

 b) 100 μ M enzyme

 c) Prolonged reaction time - days

20

25

30

35

- 27 -

Example 7

5 Alpha-Chymotrypsin ^{a)} catalyzed synthesis of L,L- and L,D-
dipeptide amides and esters using different L-amino acid
esters (50 mM) as substrates and L- or D-amino acid esters
(0.8 M) or amides as nucleophiles at pH 8.5

10	Substrate	Nucleophile	Solvent	Product	yield ^{d)}
	L-PheOEt	L-ArgNH ₂ ^{b)}	Water	PheArgNH ₂	82%
	L-TyrOEt	L-SerOEt	Water	TyrSerOEt	48% ^{c)}
	L-TyrOBzl	L-SerOEt	30% DMF	TyrSerOEt	40% ^{c)}
15	L-TyrOBzl	L-SerOMe	30% DMF	TyrSerOMe	39% ^{c)}
	L-TyrOBzl	D-serOMe	30% DMF	TyrserOMe	21% ^{c)}

a) 5 μ M

20 b) 0.4 M nucleophile

c) at 90% conversion

25 d) hydrolysis/diketopiperazine formed due to chemical insta-
bility of product was observed under these conditions in
amounts of 15-35% and is not included in the yields re-
ported.

30

35

- 28 -

Example 8

Subtilisin A ^{a)} catalyzed synthesis of sidechain protected
5 L-Aspartyl-D-alanyl amide using L-Aspartyl diesters (0.1 M)
as substrates and D-alanine amide as nucleophile at pH 8.5

10	Nucleophile		Solvent	Product	Yield
	Substrate	(conc.)			
	L-Asp(OEt) ₂	(1.0 M)	Water	Asp(OEt)alaNH ₂	9%
	L-Asp(OEt) ₂	(2.0 M)	Water	Asp(OEt)alaNH ₂	24%
	L-Asp(OBzl) ₂ ^{b)}	(0.5 M)	30% DMSO	Asp(OBzl)alaNH ₂	8%
15	L-Asp(OBzl) ₂ ^{b)}	(1.0 M)	30% DMSO	Asp(OBzl)alaNH ₂	20%

a) 5 μ M

b) 50 mM substrate, 20 μ M enzyme

20

25

30

35

- 29 -

Example 9

Elastase ^{a)} catalyzed synthesis of L,L-amides using amino
5 acid benzyl ester (50 mM) as substrate and amino acid amide
(0.5 M) as nucleophile in water at pH 8.5

Substrate	Nucleophile	Product	Yield
10 L-ValOBzl	L-Arginine amide	ValArgNH ₂	59%

^{a)} 40 μ M

15

20

25

30

35

- 30 -

Example 10

5 Synthesis of L,L-dipeptide amides catalyzed by papaya thiol-
endoproteases^{a)} using amino acid esters (50 mM) as
substrates and L-amino acid amides (0.8 M) as nucleophiles
in water at pH 8.5

10	<u>Enzyme</u>	<u>Substrate</u>	<u>Nucleophile</u>	<u>Product</u>	<u>Yield</u>
	Papain	LysOEt	AlaNH ₂	LysAlaNH ₂	60%
	Papain	LysOMe	AlaNH ₂	LysAlaNH ₂	55%
	Chymopapain	LysOEt	AlaNH ₂	LysAlaNH ₂	23%
15	Chymopapain	LysOMe	AlaNH ₂	LysAlaNH ₂	34%

a) 100 μ M, 2 mM EDTA, 10 mM Cysteine

20

25

30

35

- 31 -

Example 11

5 Clostripain ^{a)} catalyzed synthesis of L,L-dipeptide amides
and esters with L-Arginine ethyl ester as substrate (50 mM)
and L-amino acid amides as nucleophiles at pH 8.5

10	Nucleophile	(conc.)	Solvent	Product	Yield
	L-Methionine amide	(0.5 M)	Water	ArgMetNH ₂	38%
	L-Phenylalanine amide	(0.2 M)	30% EtOH	ArgPheNH ₂	6%
	L-Phenylalanine amide	(0.6 M)	30% DMF	ArgPheNH ₂	65%

15

a) 5 μ M enzyme, 50 mM CaCl₂, 10 mM DTT, pH adjusted with TEA

20

25

30

35

- 32 -

Example 12

5 Porcine Pancrease Lipase a) catalyzed synthesis of L,L-di-peptide amides using L-amino acid ethyl esters (50 mM) as substrates and L-amino acid amides as nucleophiles in 30% EtOH at pH 8.5

10	<u>Substrate</u>	<u>Nucleophile (conc.)</u>	<u>Product</u>	<u>Yield</u>
	L-TrpOEt	L-MetNH ₂ (1.5 M)	TrpMetNH ₂	71%
	L-TrpOEt	L-MetNH ₂ (1.0 M)	TrpMetNH ₂	54%
	L-TyrOEt	L-SerNH ₂ (1.5 M)	TyrSerNH ₂	69%
15	L-MetOEt	L-MetNH ₂ ^{b)} (1.0 M)	MetMetNH ₂	31% ^{c)}

a) 500 μ M

b) Reaction in pure water

20 c) At incomplete conversion

25

30

35

- 33 -

Example 13

5 Candida Cylindracea Lipase ^{a)} catalyzed synthesis of L,L-di-peptide amides using L-amino acid ethyl esters (50 mM) as substrates and L-amino acid amides as nucleophiles in 30% EtOH at pH 8.5

10	<u>Substrate</u>	<u>Nucleophile (conc.)</u>	<u>Product</u>	<u>Yield</u>
	L-TrpOEt	L-MetNH ₂ (1.5 M)	TrpMetNH ₂	75% ^{b)}
	L-TyrOEt	L-SerNH ₂ (1.5 M)	TyrSerNH ₂	50% ^{b)}

15

a) 1000 μ M, prolonged reaction time

b) versus hydrolysis at less than 50% conversion

20

25

30

35

- 34 -

Example 14

5 Preparative synthesis of L,L-Tryptophanylethionine amide,
 TrpMetNH₂

Procedure

- 10 L-Tryptophane ethyl ester hydrochloride (4.0 g, 15 mmol) and
 L-Methionine amide hydrochloride (55.7 g, 300 mmol) were
 dissolved in 195 ml H₂O and 90 ml ethanol, and pH was ad-
 justed to 8.5 with sodium hydroxide. The reaction was initi-
15 ated by addition of 0.8 g of crude Porcine Pancreatic Lipa-
 se and was kept at pH 8.5 for the duration of the reaction.
 The remainder of the substrate (4.0 g, 15 mmol) was added
 after 5 hours and the reaction continued overnight. It was
 then stopped by adjusting pH to 3 with HCl-solution.
- 20 The mixture was then diluted, ethanol was removed by evapo-
 ration under reduced pressure, and the mixture was filter-
 ed. The filtrate was purified by RP-preparative HPLC (Waters
 Prep LC/System 500A) using two columns (5.7 x 30 cm) packed
 with 60 um C-18 particles and 5 mM HCl/ethanol mixtures as
25 eluent.

 Collected fractions containing pure product were concentra-
 ted under reduced pressure and finally freeze dried.

- 30 This procedure gave 4.78 g of L,L-Tryptophanylethionine
 amide hydrochloride (12.9 mmol, 43%) as an amorphous powder.

Identification

- 35 The product was identified as the hydrochloride containing
 10.3% (w/w) of chloride.

- 35 -

Amino acid analysis showed the absence of free amino acids and gave the following results after acid hydrolysis:

Met (1.00)

5 Trp (1.00)

Specific optical rotation in 50% MeOH, $c=0.2$ using the sodium D-line was found to be $+40.0^\circ$ at 20°C .

10 Purity

HPLC-purity: 92.4% (Novapak 4 μm C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 5.3% (w/w)

Quantization of the alpha-amino group by reaction with Trinitrobenzene sulphonic acid and UV-detection: 75.8% (w/w).

20 Peptide content by UV-quantization: 88.3% (w/w) (281 nm, Trp-absorbance in MeOH: 0.1 N KOH (1:1))

25

30

35

- 36 -

Example 15

Preparative synthesis of L,D-Tyrosylserin amide, TyrserNH₂

5

Procedure

10 L-Tyrosine ethyl ester hydrochloride (2.5 g, 10 mmol) and
D-serine amide hydrochloride (17.5 g, 100 mmol) were dissolved in 200 ml of water, and pH was adjusted to 8.5 with sodium hydroxide. The reaction was initiated by addition of 50 mg of alpha-chymotrypsin and was kept at pH 8.5 for the duration of the reaction. After 30 minutes precipitation of
15 free tyrosine began. The remainder of the substrate (5.0 g, 20 mmol) was added in two portions of 2.5 g during 1 hour. The reaction was stirred for two hours and was then stopped by adjusting pH to 3 with HCl-solution.

20 The formed tyrosine was filtered off, and the filtrate was purified by RP-preparative HPLC (Waters Prep LC/System 500A) using two columns (5.7 x 30 cm) packed with 20 µm C-18 particles and 50 µM acetic acid as an eluent.

25 Collected fractions containing pure product were concentrated under reduced pressure and finally freeze dried with addition of aqueous HCl.

This procedure gave 2.8 g of L,D-Tyrosylserine amide hydrochloride
30 (9.2 mmol, 31%) as an amorphous powder.

Identification

The product was identified as the hydrochloride containing
35 16.0% (w/w) of chloride.

- 37 -

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Ser (1.10)

5 Tyr (0.90)

Specific optical rotation in 50% MeOH, $c=0.3$ using the sodium D-line was found to be $+58.0^\circ$ at 20°C .

10 Purity

HPLC-purity: 97.4% (Novapak 4 μm C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 1.8% (w/w).

Quantization of the alpha-amino group by reaction with Trinitrobenzene sulphonic acid and UV-detection: 81% (w/w).

20

25

30

35

- 38 -

Example 16

5 Preparative synthesis of D,L-tyrosylLeucin amide, tyrLeuNH₂Procedure

10 D-tyrosine ethyl ester hydrochloride (3.5 g, 14 mmol) and
L-Leucin amide hydrochloride (14 g, 84 mmol) were dissolved
in 246 ml of 0.1 M KCl and pH was adjusted to 9.0 with sodium
hydroxide. The reaction was initiated by addition of 0.7
g of alpha-chymotrypsin and stirred for two days at room
15 temperature. pH was kept at 9.0 for the duration of the re-
action. The reaction was stopped by adjusting pH to 3 using
HCl-solution.

The formed tyrosine was filtered off, and the filtrate was
purified by RP-preparative HPLC (Waters Prep LC/System 500A)
20 using two columns (5.7 x 30 cm) packed with 20 µm C-18 par-
ticles and 5 mM HCl as an eluent.

Collected fractions containing pure product were concentra-
ted by evaporation under reduced pressure and finally freeze
25 dried.

This procedure gave 2.50 g of D,L-tyrosylLeucine amide hy-
drochloride (7.6 mmol, 54%) as an amorphous powder.

30 Identification

The product was identified as the hydrochloride containing
9.8% (w/w) of chloride.

35

- 39 -

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Tyr (0.98)

5 Leu (1.03)

Specific optical rotation in water, $c=0.1$ using the sodium D-line was found to be -129.4° at 20°C .

10 Purity

HPLC-purity: 92.9% (Novapak 4 μm C-18, 0.1 M ammonium phosphate, pH 3.0/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 6.8% (w/w).

Quantization of the alpha-amino group by reaction with Trinitrobenzen sulfonic acid and UV-detection: 74.9%

20 UV-quantization: 74.9% (Tyrosine phenolate absorbance at 293 nm, in 0.1 M KOH)

25

30

35

- 40 -

Example 17

Preparative synthesis of L,L-ArginylMethionine amide, Arg-
5 MetNH₂

Procedure

L-Arginine ethyl ester dihydrochloride (4.1 g, 15 mmol) and
10 L-Methionine amide hydrochloride (55.4 g, 300 mmol) were
dissolved in 300 ml of water, and pH was adjusted to 8.5
with sodium hydroxide. The reaction was initiated by addi-
tion of 50 mg of trypsin. pH was kept at 8.5 for the dura-
tion of the reaction. The remainder of the substrate (8.2 g,
15 30 mmol) was added during one hour. The reaction was then
stopped by adjusting pH to 3 using HCl-solution.

The reaction mixture was then diluted and purified by suc-
cessive cation exchange on a DOWEX A650 Wx4 and a CM-Sepha-
20 rose 6B column using ammonium acetate and NaCl/HCl salt gra-
dients, respectively, and was finally desalted.

Collected fractions containing pure product were concentra-
ted under reduced pressure and finally freeze dried.

25 This procedure gave 10.7 g of L,L-ArginylMethionine amide
dihydrochloride (28.3 mmol, 63%) as a white amorphous pow-
der.

30 Identification

Less than 0.2% (w/w) of acetate and 22.9% (w/w) of chloride
were measured, so the product was present as a dihydrochlo-
ride.

35

- 41 -

Amino acid analysis showed the absence of free amino acids, but following acid hydrolysis gave the following results:

Arg (1.00)

5 Met (0.80)

Specific optical rotation in 50% MeOH, $c=0.2$ using the sodium D-line was found to be $+19.5^\circ$ at 20°C .

10 Purity

HPLC-purity: 95.1% (Novapak C-18, 0.1 M ammonium phosphate containing alkylsulfonate, pH 4.5/acetonitrile, 220 nm)

15 Water content by Karl Fisher: 9.1% (w/w).

Peptide content by amino acid analysis: 72% (w/w) based on Arginine.

20

25

30

35

- 42 -

Example 18

5 Synthesis of L,L-Methionyl-Methionine amide catalyzed by Eupergit C immobilized Porcine Pancreatic Lipase a) using L-Methionine ethyl ester as substrate and L-Methionine amide as nucleophile at pH 8.5 in water and water/organic homogeneous mixtures.

10	Conc. of substrate	Nucleophile	%	Organic solvent	Yield b)
	50 mM	1.0 M	0	-	68%
	100 mM	0.5 M	30	Isopropanol	26%
15					

a) Porcine Pancreatic Lipase was immobilized on Eupergit C using the procedure recommended by the manufacturer to a final concentration corresponding to approx. 400 μ M on the gel by activity assay.

b) The reaction mixtures with volumes of 1-3 reaction bed volumes were recirculated over the column packed with enzyme gel until full conversion of the substrate as determined by HPLC (0.5-2 days) while pH was being kept constant by pH-stat control.

30

35

- 43 -

Example 19

5 Porcine Pancreatic Lipase ^{a)} and alpha-chymotrypsin ^{a)} catalyzed synthesis of L,L-Tryptophanyl-Alanine-tert-butylester in pure organic solvents with L-Tryptophane ethyl ester (50 mM) as substrate and L-Alanine-tert-butylester (0.3 M) as nucleophile, both in saltfree form.

10

Enzyme ^{a)}		Solvent	Conversion ^{c)}	Yield ^{c)}
	PPL	CH ₂ Cl ₂ /n-Hexane (1:3)	30%	13%
	CT	CH ₂ Cl ₂ /n-Hexane (1:3)	56%	17%
15	PPL	CH ₂ Cl ₂	7%	10%
	CT	CH ₂ Cl ₂	50%	3%
	PPL ^{b)}	CH ₂ Cl ₂ /Isooctane (1:1)	82% ^{b)}	26%

20 ^{a)} 500-2000 μ M freeze-dried enzyme containing moisture was added directly to the mixture, which was stirred for 24 hours.

25 ^{b)} In this case, 500 μ M enzyme and 3 days of reaction time were applied.

30 ^{c)} Conversion of starting material and yield versus hydrolysis was determined by HPLC of samples quenched with DMF, evaporated and redissolved in DMF/acid water. Controls showed neither conversion nor yield.

35

Example 20

Alpha-chymotrypsin a) catalyzed synthesis of sidechain protected L,L-dipeptide amides with L-Tyrosine or L-Phenylalanine ethyl esters (50 mM) as substrates and L-S-Acetamidomethylcystein amide (0.6 M) as nucleophiles in water at pH 8.5.

10

<u>Substrate</u>	<u>Product</u>	<u>Yield</u>
L-Tyrosine ethyl ester	TyrCys(-SAcM)NH ₂	62%
L-Phenylalanine ethyl ester	PheCys(-SAcM)NH ₂	78%

15

a) 5 μ M

20

25

30

35

Example 21

5 Alpha-chymotrypsin a) catalyzed synthesis of L,L-Dipeptide
alcohols using L-Tyrosine and L-Phenylalanine ethyl esters
(50 mM) as substrates and L-Amino acid alcohols (0.5 M) as
nucleophiles in water at pH 8.5.

10

<u>Substrate</u>	<u>Nucleophile</u>	<u>Product</u>	<u>Yield</u>
L-TyrOEt	L-MetCH ₂ OH	TyrMetCH ₂ OH	42%
L-TyrOEt	L-LeuCH ₂ OH	TyrLeuCH ₂ OH	46%
L-PheOEt	L-MetCH ₂ OH	PheMetCH ₂ OH	60%

15

a) 10 μ M

20

25

30

35

- 46 -

Example 22

Synthesis of L,L-dipeptides catalyzed by thiolendoproteases

- 5 a) using amino acid ethyl esters (50 mM) as substrate and free L-Amino acids as nucleophiles in water at pH 8.5.

	Enzyme	Substrate	Nucleophile	(conc.)	Product	Yield b)c)
10	Ficin	ArgOEt	ArgOH	(1.0 M)	ArgArgOH	6%
	Papain	ArgOEt	ArgOH	(1.0 M)	ArgArgOH	7%
	Ficin	LysOEt	AlaOH	(1.5 M)	LysAlaOH	5%
	Papain	LysOEt	AlaOH	(1.5 M)	LysAlaOH	6%

15

a) 100 μ M, 2 mM EDTA, 0.1 M KCl, 5 mM DTT or 10 mM cysteine.

b) Determined vs. hydrolysis via a standard at less than 50% conversion.

20

c) Controls without enzyme showed no detectable aminolysis under the conditions reported.

- 47 -

Example 23

Trypsin a) catalyzed synthesis of L,L-dipeptide amides with
5 Arginine-paranitroanilide (10 mM) as substrate and L-Amino
acid amides (0.3 M) as nucleophiles in 40% DMF at pH 8.5.

10	Nucleophile	Product	Yield b)
	Methionine amide	ArgMetNH ₂	45%
	Leucine amide	ArgLeuNH ₂	31%
	Tyrosine amide	ArgTyrNH ₂	14%

15

a) 5 μ M

b) Determined vs. hydrolysis via a standard at less than 80%
conversion.

20

25

30

35

- 48 -

Example 24

Papain a)^{b)} catalyzed synthesis of L,L-Lysyl-Alanine amide
5 using L-Lysine ethyl ester (50 mM) as substrate and L-Alanine
amide (0.8 M) as nucleophile in water at various pH-values.

10	pH	Yield c)
	6.5	21%
	4.5	47%

15

a) 50 μ M, 2 mM EDTA, 10 mM Cysteine.

b) At prolonged reaction time; less than 50% conversion.

20

c) Determined vs. hydrolysis using a standard and corrected
for incomplete conversion.

25

30

35

Example 25

Alpha-chymotrypsin a) and clostripain b) catalyzed synthesis
5 of L,L-dipeptide esters using L-Amino acid ethyl esters (50
mM) as substrates and L-Amino acid ethyl or tert-butyl-
esters as nucleophiles in water at pH 7.5 and 8.5.

10	<u>Enzyme</u>	<u>Substrate</u>	<u>Nucloephile</u>	<u>(conc.)</u>	<u>Product</u>	<u>Yield</u>
	CT	TrpOEt	AlaOtBu	(0.8 M)	TrpAlaOtBu	12%
	CT	TrpOEt	ValOEt	(0.8 M)	TrpValOEt	18%
	CL	ArgOEt	MetOEt	(1.0 M)	ArgMetOEt	33% c)

15 a) 5 μ M, 0.1 M KCl, pH 7.5.

b) 10 μ M, 50 mM CaCl₂, 10 mM DTT, pH 8.5 adjusted with TEA.

20 c) Determined at less than 50% conversion.

25

30

35

- 50 -

Example 26

Porcine Pancreatic Lipase ^{a)} and Lipolase (Novo)(LIP) ^{a)} and
 5 Rhizopus Arrhizus Lipase (RA) ^{b)} catalyzed synthesis of L,L-
 Methionyl-Methionine amide using different L-Methionine
 esters as substrates and L-Methionine amide as nucleophile
 in various aqueous/organic solvent homogeneous mixtures at
 pH 8.5 and 1.0 M nucleophile, unless otherwise indicated.

10

	Enzyme	Ester substrate	(conc.)	%	Organic solvent	Yield ^{e)}
15	PPL ^{c)}	Ethyl	(50 mM)	0	-	55%
	PPL ^{d)}	Ethyl	(50 mM)	0	-	36%
	PPL	Ethyl	(150 mM)	0	-	42%
	PPL	Ethyl	(200 mM)	15	Dimethoxy Ethane	20%
	PPL	Ethyl	(150 mM)	30	Isopropanol	36%
20	PPL	Ethyl	(50 mM)	90	Ethylene Glycol	42%
	PPL	n-Propyl	(50 mM)	0	-	55%
	PPL	n-Hexyl	(50 mM)	0	-	39%
	LIP	Ethyl	(50 mM)	0	-	47%
	LIP	Ethyl	(50 mM)	15	Dimethoxy Ethane	35%
25	LIP	n-Hexyl	(50 mM)	0	-	32%
	RA	Ethyl	(50 mM)	30	Ethanol	23%

a) 1000 μ M - 2000 μ M

30 b) 50 μ M

c) pH 9.0

d) At 0.25 M nucleophile

e) Various minor amounts of deamidation of product was noted
 under these conditions and is not included in the yields
 35 reported.

- 51 -

Example 27

Trichoderma Viridae Cellulase catalyzed synthesis of
5 L,L-TyrGlyNH₂ using L-Tyrosine ethyl ester as a substrate
and Glycine amide as nucleophile in water.

	Substrate (conc.)	Nucleophile (conc.)	Product	Yield ^{c)}
10				
	TyrOEt ^{a)} (20 mM)	GlyNH ₂ (0.6 M)	TyrGlyNH ₂	23%
	TyrOEt ^{b)} (10 mM)	GlyNH ₂ (0.8 M)	TyrGlyNH ₂	34%

15 a) 1000 μ M crude enzyme, pH 8.5

b) 500 μ M crude enzyme, pH 8.0

c) Determined vs. hydrolysis at less than 30% conversion and
corrected for hydrolysis and aminolysis found in con-
20 trols at similar conditions.


25

30


35

P a t e n t C l a i m s :


1. A process for producing dipeptides or structurally
5 related compounds having the general formula



wherein A represents an optionally side-chain protected L-
10 or D- α -amino acid residue or ω -amino acid residue and B
represents an optionally side-chain protected L- or D- α -
aminocarboxylic acid residue which may be the same as or
different from A, an L- or D-aminophosphonic acid residue
or L- or D-aminosulfonic acid residue or the corresponding
15 ω -amino acids or salts and hydrates thereof, and Y is OH,
H, alkyl, aryl, aralkyl or a C-terminal blocking group, or
BY represents an amino alcohol residue



20 wherein B^1 is a decarboxy derivative of the amino-
carboxylic acids as defined with relation to B, and Y^1 is
H, alkyl, aryl or aralkyl, c h a r a c t e r i z e d by
reacting a substrate component, which is an amino acid
25 derivative having the formula



30 wherein A is as defined above, R^1 represents alkyl, aryl
or aralkyl optionally substituted with inert substituents
or an α -des-amino fragment of an amino acid, and R^2 and
 R^3 are the same or different and each represents hydrogen,
alkyl, aryl or aralkyl optionally substituted with inert
35 substituents,


with a nucleophile component selected from

(a) amino acids having the formula




wherein B is an aminocarboxylic acid residue as defined above,

10 (b) amino acid amides having the formula




15 wherein B is an aminocarboxylic acid residue as defined above, and R^2 and R^3 have the above meaning, except that when R^2 represents hydrogen, R^3 may also represent hydroxy or amino,

20 (c) amino acid esters having the formula




25 wherein B is an aminocarboxylic acid residue as defined above, and R^4 represents alkyl, aryl or aralkyl,

(d) optionally acid group protected straight chain or branched aminophosphonic acids or aminosulfonic acids
30 having the formula



wherein R^5 , R^6 and R^7 independently represent hydrogen,
35 alkyl, aryl or aralkyl, x is 1-6 and z is 2-12,


(e) amino acid aldehydes or ketones or derivatives thereof having the formula



5

wherein B^1 is as defined above, Y^2 is O or a functional derivative thereof, preferably a ketal, and R^8 is H, alkyl, aryl or aralkyl, and

10 (f) amino alcohols having the formula



wherein B^1 and Y^1 have the above meaning

15

in the presence of an amidase or esterase enzyme different from serine or thiol carboxypeptidases in solution or dispersion, and then, if desired, cleaving a present side-chain protecting group or protective group Y and/or, if
20 desired, converting the resulting dipeptide derivative to a salt or hydrate.

2. A process according to claim 1, characterized by using an enzyme with esterase or amidase
25 activity selected from serine or thiolendoproteases, lipases, esterases and glycosidases.

3. A process according to claim 1 or 2, characterized in that the enzyme used has been chemically
30 modified or is a biosynthetic mutant of a natural form.

4. A process according to any of the preceding claims, characterized by using an immobilized enzyme.

35 5. A process according to any of the preceding claims, characterized by using an aqueous reaction

solution or dispersion containing 0-90%, preferably 0-60%, of a polar water miscible organic solvent and having a pH value of 3-11, preferably 5-10.5, more preferably 6-10, in particular 7-9.5.

5

6. A process according to claim 5, characterized in that the organic solvent is selected from alkanols, dimethyl sulfoxide, dimethyl formamide, dimethoxy ethane and ethylene glycol.

10

7. A process according to any of claims 1 to 4, characterized by using an organic reaction solution or dispersion containing 0-10% of water.

15

8. A process according to claim 7, characterized by using an unpolar organic solvent, preferably selected from dialkyl ethers, ethyl acetate, ethyl propionate, octanes, heptanes, hexanes, petroleum ether and methylene chloride.

20

9. A process according to claim 7, characterized by using a liquid substrate or nucleophile component which may also serve as the organic solvent.


25

10. A process according to any of the preceding claims, characterized by using as substrate component a D- or L-amino acid ester selected from benzyl esters or straight or branched C₁-C₈ alkyl esters optionally substituted with inert substituents.

30


11. A process according to any of the preceding claims, characterized by using as nucleophile component an amino acid amide having the formulae

35



wherein R^3 is hydrogen or C_1 - C_3 alkyl and B is an L- or D-amino carboxylic acid residue.

12. A process according to any of claims 1 to 10,
5 c h a r a c t e r i z e d by using as nucleophile component an ester having the formula



- 10 wherein B is a L- or D-aminocarboxylic acid residue and R^* is C_1 - C_3 alkyl.

13. A process according to any of the preceding claims,
c h a r a c t e r i z e d in that the resulting dipeptide
15 includes one or more C-terminal protective groups Y, and that the group or groups are cleaved enzymatically, either by means of the same enzyme as was used in the preceding reaction or by means of an enzyme having a different ester or amide specificity.


- 20
14. A process according to any of the preceding claims,
c h a r a c t e r i z e d in that the resulting dipeptide includes one or more side-chain protective groups and that the group or groups are cleaved enzymatically, preferably
25 by means of an esterase or lipase or proteolytical enzyme.

30

35

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK89/00193

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC 4		
C 12 P 21/02, C 07 K 1/00		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC 4	C 07 K 1/00-/14; C 12 P 21/00,/02	
US C1	435:68-70; 195:4,29,30	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
SE, NO, DK, FI classes as above.		
III. DOCUMENTS CONSIDERED TO BE RELEVANT*		
Category *	Citation of Document, ** with Indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
Y	EP, A2, 0 269 390 (GENENCOR INC.) 1 June 1988 see page 2 lines 33-60	1-14
Y	EP, A2, 0 220 923 (W.R. GRACE & CO) 6 May 1987 see claim 1 & EP, 86308176 US, 4710583 US, 4810817 JP, 62142199	1-14
Y	EP, A1, 0 074 095 (TOYO SODA MANUFACTURING CO., LTD) 16 March 1983 & EP, 82108117 JP, 58043793 US, 4506011 CA, 1195272 JP, 58063394	1-14
.../...		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: 10</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
1989-10-23	1989 -11- 14	
International Searching Authority	Signature of Authorized Officer	
Swedish Patent Office	 Wonne Siösteen	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	EP, A2, 0 154 472 (AJINOMOTO CO., INC.) 11 September 1985 & EP, 85301229 JP, 60186299 US, 4666838 JP, 61035796	1-14
Y	EP, A1, 0 017 485 (DE FORENEDE BRYGGERIER A/S) 15 October 1980 see page 5, lines 1-5, pages 6-7 and the claims & WO, 80/02157 US, 4339534 CA, 1160973 AT,E, 9595 CA, 1177429 AU, 545416 US, 4806473	1-14
P,X	EP, A1, 0 278 787 (CARLSBERG BIOTECHNOLOGY LTD. A/S) 17 August 1988 & WO, 88/06187	1-14